However, this additional novel information is not sufficient alone to support antiatherogenic interventions via IL-1β inhibition, as the CANTOS trial indicated that a general reduction of IL-1β also carries the risk of potentially fatal infections (87). This evidence concerns the gene IL1B and infection.